Quiz
What is esketamine indicated to treat?
News
04/01/2026
Brionna Mendoza
A Phase 2b randomized clinical trial published in JAMA Psychiatry found nonsignificant differences in response rate between psilocybin 25 mg, psilocybin 5 mg, and placebo with supporting psychotherapy in treatment-resistant major depressive...
A Phase 2b randomized clinical trial published in JAMA Psychiatry found nonsignificant differences in response rate between psilocybin 25 mg, psilocybin 5 mg, and placebo with supporting psychotherapy in treatment-resistant major depressive...
A Phase 2b randomized clinical...
04/01/2026
Psych Congress Network
Conference Insights
03/27/2026
Kristian Dambrino, DNP, APRN, MSN
Kristian Dambrino, DNP, PMHNP-BC, shares practical, patient-centered strategies for selecting antidepressants in major depressive disorder (MDD).
Kristian Dambrino, DNP, PMHNP-BC, shares practical, patient-centered strategies for selecting antidepressants in major depressive disorder (MDD).
Kristian Dambrino, DNP,...
03/27/2026
Psych Congress Network
News
03/27/2026
Brionna Mendoza
A phase 2b randomized clinical trial found that inhaled GH001, a synthetic formulation of mebufotenin, produced rapid antidepressant effects in adults with treatment-resistant depression (TRD).
A phase 2b randomized clinical trial found that inhaled GH001, a synthetic formulation of mebufotenin, produced rapid antidepressant effects in adults with treatment-resistant depression (TRD).
A phase 2b randomized clinical...
03/27/2026
Psych Congress Network
News
03/24/2026
Brionna Mendoza
Research presented at NP Institute highlights α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor modulation as a promising therapeutic target.
Research presented at NP Institute highlights α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor modulation as a promising therapeutic target.
Research presented at NP...
03/24/2026
Psych Congress Network
